Xerox Corporation (NYSE:XRX) [Trend Analysis] luring active investment momentum, shares a loss remains unchanged to $9.13. A shareholder rights firm, Lundin Law PC reported a class action against Xerox Corporation (XRX) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Xerox shares between April 23, 2012 and October 23, 2015, are reminded to contact the firm before the December 23, 2016 lead plaintiff motion deadline.
According to the Complaint, Xerox repeatedly touted its new software product, Health Enterprise, as an important growth area for the Company, which would operate at low cost and high profit margin.
Xerox’s statements pertaining to the profitability and growth prospects of the Health Enterprise business were materially false and misleading because Xerox failed to disclose: that the Company’s existing Health Enterprise projects were experiencing major delays and cost overruns; that Xerox would be unable to deliver Health Enterprise implementations at sustainable profits; and that as a result of the above, the Company’s statements about its business, operations, and prospects lacked a reasonable basis. The total volume of 8 Million shares held in the session was surprisingly higher than its average volume of 9269.14 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -47.90%, and looking further price to next year’s EPS is 0.36%. While take a short look on price to sales ratio, that was 0.52 and price to earning ratio of 15.07 attracting passive investors.
Shares of Rennova Health, Inc. (NASDAQ:RNVA) [Trend Analysis] runs in leading trade, it moving down -30.62% to traded at $0.09. The firm has price volatility of 37.92% for a week and 32.45% for a month. Its beta stands at -0.31 times. Rennova Health, Inc. (NASDAQ:RNVA) declared that pricing of an underwritten public offering of 12,350 shares of its Series H Convertible Preferred Stock at a per share price to the public of $1,000. The Series H Preferred Stock has a stated value of $1,000 per share with each share convertible into 11,111 shares of common stock, at a conversion price of $0.09 per share. The gross proceeds to Rennova Health, Inc. from this offering are expected to be approximately $12,350,000 before deducting underwriting discounts and commissions and other estimated offering expenses.
Approximately $8,300,000 of the net proceeds from this offering will be used to redeem certain outstanding shares of Rennova Health’s Series G Convertible Preferred Stock. The offering is expected to close on December 20, 2016, subject to customary closing conditions. Aegis Capital Corp. is acting as the sole book-running manager for the offering. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective on December 15, 2016. Narrow down four to firm performance, its weekly performance was -0.76% and monthly performance was 61.89%. The stock price of RNVA is moving down from its 20 days moving average with -21.20% and isolated negatively from 50 days moving average with -30.53%.